Dr. Tarec Christoffer El-Galaly
Professor, Aarhus University
Consultant Hematologist, Aarhus University Hospital
Chair, Danish Lymphoma Group and The Nordic Lymphoma Epidemiology Group
Tarec Christoffer El-Galaly is a consultant hematologist and professor at Aarhus University Hospital and Aarhus University. His main clinical and research area is lymphoid malignancies with a focus on outcomes research and epidemiology. He has published >150 papers and is involved in many national and international activities related to research in lymphoma and clinical guidelines. He is chair of the Danish Lymphoma Group and The Nordic Lymphoma Epidemiology Group.
Dr. Kostas Stamatopoulos
Research Director, Institute of Applied Biosciences at CERTH, Thessaloniki, Greece
Visiting Professor, Karolinska Institute, Stockholm, Sweden
Kostas Stamatopoulos is a specialist in Hematology, Research Director at the Institute of Applied Biosciences at CERTH, the Center for Research and Technology Hellas, Thessaloniki, Greece. He also holds the position of Visiting Professor at the Karolinska Institute, Stockholm, Sweden. Dr Stamatopoulos is the Scientific Coordinator of GRECRIN, the Greek Clinical Infrastructure Network; national representative in the EU Cancer Mission; member of the Research and European Affairs Committes of the European Hematology association; Board member of ERIC, the European Research Initiative on chronic lymphocytic leukemia; Steering Committee member of the Scientific Working Group on Precision Hematology of the European Hematology Association. Between 2018-2021 he has served as Coordinator of the Hellenic Precision Medicine in Oncology. His research interests include: precision medicine in cancer; immunobiology of lymphoid malignancies with a particular focus on CLL; and, patient empowerment in care.
Dr. Julio Delgado
Head, Oncoimmunotherapy Unit, Hospital ClÃnic, Barcelona (HCB)
Consultant Haematologist, Hospital ClÃnic, Barcelona (HCB)
Researcher, IDIBAPS Biomedical Research Institute
Associate Professor, University of Barcelona
Dr. Julio Delgado is the Head of the Oncoimmunotherapy Unit and consultant haematologist at Hospital ClÃnic, Barcelona (HCB), researcher at IDIBAPS Biomedical Research Institute, and associate professor at the University of Barcelona. He has been involved in the clinical development of ARI-0001 (varnimcabtagene autoleucel), the first 100% academic CART-cell product ever approved in an EU member state. He is a founding member of the Spanish Group for chronic lymphocytic leukaemia (CLL) and runs most CLL and CART-cell clinical trials at HCB. He is a core member of the EMA’s Scientific Advisory Group for Oncology, and advisor to the Spanish Medicines Agency and the Catalan Pharmacotherapy Committee. He is a member of HCB’s Advanced Therapies Committee and vice-president of the Institution’s Review Board/Ethics Committee. He is a past member of the EHA’s Education Committee and current member of the EHA’s European Affairs Committee. He is also the EHA’s representative at EMA’s health-care professionals working party (HCPWP). He has co-authored over 200 peer-reviewed papers.